NASHVILLE, Tenn. / Apr 01, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Monica Cintado has been appointed as senior vice president of development, effective immediately.
In this role, Cintado will lead HCA Healthcare’s enterprise development strategy, overseeing mergers, acquisitions, divestitures and strategic investments. She will also guide market analysis, partnership initiatives and real estate strategies to support HCA Healthcare’s long-term growth.
“Monica is a highly regarded and experienced healthcare development executive and she has played an instrumental role in the growth of HCA Healthcare,” said Mike McAlevey, executive vice president and chief legal and administrative officer for HCA Healthcare. “Her demonstrated ability to identify, evaluate and execute upon inorganic opportunities will continue to be an invaluable resource to the Company as she steps into her new role.”
Cintado first joined HCA Healthcare in 1993, working in Operations and International Development for six years. She returned to the Company in 2015 as vice president of development, helping to build key relationships and development strategies for partnerships and acquisitions. In 2019, Cintado also assumed leadership of the Corporate Development team, overseeing strategy, due diligence, negotiations and regulatory approvals for acquisitions and divestitures.
Prior to rejoining HCA Healthcare, Cintado was senior vice president of development at United Surgical Partners International, where she led joint ventures with not-for-profit systems and participated in U.S. and international hospital acquisitions. She holds an undergraduate degree from Vanderbilt University and a masters of business administration from Rollins College.
Cintado succeeds Joe Sowell, who is retiring after over 15 years with the Company. During that time, Sowell helped shape HCA Healthcare’s corporate strategies and executed numerous complex transactions.
“Joe has played an important role in the growth of HCA Healthcare,” said McAlevey. “His focus on advanced technologies and standardized processes, as well as his commitment to best practices and continuous improvement, have made our development team stronger. We wish him all the best in his retirement.”
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its approximately 44 million annual patient encounters to advance science, improve patient care and save lives.
All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.
Last Trade: | US$378.98 |
Daily Change: | 2.40 0.64 |
Daily Volume: | 1,260,655 |
Market Cap: | US$91.170B |
April 25, 2025 February 20, 2025 February 18, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load